Clinical features of long-term low-dose @entity4677 treatment for XXXX .

@entity1 @entity4677 @entity410 @entity29279 @entity302
BACKGROUND: The aim of this study was to assess the rate of response to long-term low-dose @entity4677 ( @entity29279 ) treatment and the clinical factors associated with response. METHODS: The response to low-dose @entity29279 of 43 @entity1 with @entity302 (22 male, 21 female; age range, 5-39 years; median age, 13   years) was retrospectively assessed. @entity1 aged <15   years received <20   mg/kg/day @entity29279 , whereas those aged >= 15   years received <1000   mg/day @entity29279 . Clinical features were compared between responders to low-dose @entity29279 , responders to the recommended dose, and non-responders. RESULTS: Of the 43 @entity1 who received low-dose @entity29279 , 13 (30%) showed improvement, defined as @entity410 cessation or >75% @entity410 reduction over 6   months for @entity1 with monthly, weekly, and daily @entity410 ; and over 1   year for @entity1 with yearly @entity410 . Efficacy was maintained for >1   year in 10 (77%) of the 13 @entity1 . Long-term response to low-dose @entity29279 was significantly associated with older age at onset and fewer previous treatments with ineffective anti- @entity302 drugs. All @entity1 showing long-term response to low-dose @entity29279 developed only focal @entity410 . CONCLUSIONS: Titration of @entity29279 starting from a low dose may be effective in selected @entity1 . Once @entity1 respond to low-dose treatment, maintenance of the effective dosage may prolong response.
